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Abstract
Background:  Successful  heart  transplantation  depends  largely  on  donor  heart  function.  During
brain death  many  hormonal  changes  occur.  These  events  lead  to  the  deterioration  of  the  donor
hearts. The  2002  Crystal  Consensus  advises  the  use  of  a  triple  hormonal  scheme  to  rescue
marginal cardiac  organs.
Material  and  methods:  A  prospective,  longitudinal  study  was  conducted  on  potential  donor
hearts during  the  period  1  July  2011--31  May  2013.  All  donor  hearts  received  a  dual  hormonal
rescue scheme,  with  methylprednisolone  15  mg/kg  IV  and  200  mcg  levothyroxine  by  the  enteral
route. There  was  at  least  a  4  h  wait  prior  to  the  harvesting.  The  preload  and  afterload  was  opti-
mised. The  variables  measured  were:  left  ventricular  ejection  fraction  cardiac  graft  recipient;
immediate  and  delayed  mortality.
Results:  A  total  of  30  orthotopic  heart  transplants  were  performed,  11  female  and  19  male
patients, with  age  range  between  19  and  63  years-old  (Mean:  44.3,  SD  12.92  years).  The  donor
hearts were  7  female  and  23  male,  with  age  range  between  15  and  45  years-old  (mean  22.5,
SD 7.3  years).  Immediate  mortality  was  3.3%,  3.3%  intermediate,  and  delayed  3.3%,  with  total
30 day-mortality  of  10%.  Month  survival  was  90%.  The  immediate  graft  left  ventricular  ejection
fraction was  45%,  60%  intermediate,  and  68%  delayed.  The  causes  of  death  were:  1  primary
graft dysfunction,  one  massive  pulmonary  embolism,  and  one  due  to  nosocomial  pneumonia.
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Conclusion:  It  was  concluded  that  the  use  of  double  rescue  scheme  hormonal  therapy  is  useful
for the  recovery  and  preservation  of  the  donor  hearts.  This  scheme  improves  survival  within
the ﬁrst  30  days  after  transplantation.
©  2015  Academia  Mexicana  de  Cirug´ıa  A.C.  Published  by  Masson  Doyma  Me´xico  S.A.  This  is  an
open access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
PALABRAS  CLAVE
Trasplante  cardiaco;
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Terapia  hormonal  de  rutina  en  el  donador  para  trasplante  cardiaco
Resumen
Antecedentes:  El  éxito  de  un  trasplante  cardiaco  depende  en  gran  parte  de  la  función  del
corazón donado  a  que,  durante  la  muerte  cerebral  ocurren  cambios  hormonales  importantes
y estos  conducen  al  deterioro  del  órgano  donado;  por  lo  que  el  Consenso  Cristal  de  2002
recomienda  el  uso  de  triple  esquema  hormonal  para  el  rescate  de  los  órganos  cardiacos
marginales.
Material y  métodos:  Estudio  prospectivo,  longitudinal.  Reunimos  a  potenciales  donadores  de
corazón durante  el  periodo  del  1  de  julio  del  2011  al  31  de  mayo  del  2013.  Todos  recibieron
doble esquema  de  rescate  hormonal,  con  metilprednisolona  15  mg/kg  por  vía  intravenosa  y
levotiroxina  200  g  por  vía  enteral.  Se  esperó  un  lapso  mínimo  de  4  h  antes  de  la  procuración.
Se optimizaron  la  precarga  y  poscarga.  Se  evaluaron:  mortalidad  del  receptor  y  fracción  de
expulsión del  ventrículo  izquierdo,  del  injerto  inmediata,  mediata  y  tardía.
Resultados:  Fueron  realizados  30  trasplantes  cardiacos  ortotópicos,  en  11  mujeres  y 19  varones,
con edad  promedio:  44.3  ±  12.92  (rango  19-63  an˜os).  Los  donadores  de  corazón,  7  mujeres  y  23
hombres,  con  rangos  de  edad  de  15  a  45  an˜os  (promedio  22.5  ±  7.3).  La  mortalidad  inmediata
fue del  3.3%,  mediata  3.3%  y  tardía  3.3%.  La  sobrevida  al  mes  fue  del  90%.  La  fracción  de
expulsión del  ventrículo  izquierdo  del  injerto  fue  45%  inmediata,  mediata  60%  y  tardía  68%.
Las causas  de  mortalidad  fueron:  disfunción  primaria  del  injerto  (un  caso),  una  tromboembolia
pulmonar  masiva  y  una  neumonía  nosocomonial.
Conclusión:  El  uso  de  doble  esquema  de  terapia  de  rescate  hormonal  es  útil  para  la  recuperación
y la  preservación  del  corazón  y  mejora  la  sobrevida  dentro  de  los  primeros  30  días  postrasplante.
© 2015  Academia  Mexicana  de  Cirug´ıa  A.C.  Publicado  por  Masson  Doyma  Me´xico  S.A.  Este  es  un
art´ıculo Open  Access  bajo  la  CC  BY-NC-ND  licencia  (http://creativecommons.org/licencias/by-
nc-nd/4.0/).
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Since  Dr.  Christian  Barnard1 performed  the  ﬁrst  heart  trans-
plant  in  1967,  heart  transplant  success  has  lain  in  the  control
of  acute  or  hyperacute  rejection,  and  long  term  survival.2
A  key  point  in  the  control  of  these  factors  came  about  with
the  advent  of  calcineurin  inhibitors  in  1987.
A  new  challenge  was  simultaneously  presented,  upon
which  the  success  of  a  heart  transplant  outcome  depends:
primary  graft  dysfunction  and  sufﬁcient  assessment  to
obtain  an  optimum  donor  heart,  mainly  from  marginal  car-
diac  organs  donated.
During  brain  death  a  number  of  hormonal,  metabolic  and
systemic  changes  occur,  including:  the  reduction  of  circulat-
ing  thyroid  hormones,3 the  depletion  of  vasopressin  reserves
after  6  h,4 raised  inﬂammatory  response5 and  the  well  known
‘‘adrenergic  storm’’.6,7 All  these  hormonal,  metabolic  and
systemic  changes  will  lead  to  function  deterioration  of  the
donor  heart,  and  to  the  increase  in  acute  posterior  rejection
of  the  transplanted  organ.8 Due  to  the  above  and  since  its
acceptance  in  the  2002  Crystal  Consensus,  a  triple  hormonal
scheme  to  rescue  marginal  donor  cardiac  organs9 has  been
t
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dmplemented  and  there  have  been  many  reports  of  increases
f  solid  organs  recuperated  with  the  use  of  this  scheme  or
lgorhythm.10
We  are  reporting  our  experience  based  on  the  Crystal
onsensus  scheme,  with  its  modiﬁcation,  which  consists  in
sing  it  in  all  potential  heart  donors,  with  normal  left  ven-
ricle  ejection  fraction,  in  a  routine  manner  and  not  only
n  marginal  transplants,  as  our  main  source  of  donors  is  dis-
ant  procurements.  We  report  its  repercussion  in  immediate
ostoperative  survival  and  the  single  use  of  a dual  hormonal
cheme  with  steroids  and  thyroid  hormone  by  the  enteral
oute  through  a  nasogastric  tube.
aterial and methods
e  conducted  a  prospective,  longitudinal  study  which  began
n  July  1,  2011  and  terminated  on  May  31,  2013.  All  poten-
ial  heart  donors,  aged  between  15  and  45  and  of  both  sexes
ere  brought  together.  The  potential  donors  were  initially
ssessed  using:  anthropometry,  electrocardiogram,  echocar-
iogram  (if  available)  and  laboratory  testing.  If  optimum
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riteria  were  met  for  heart  donation  (in  accordance  with
ur  protocol)  and  any  other  heart  condition  was  ruled  out,
ormonal  therapy  administration  was  initiated  with  methyl-
rednisolone  15  mg/kg  intravenously  (IV)  by  bolus  injection
nd  200  mcg  of  levothyroxine  in  nasogastric  tube  with  a
epeated  dose  of  the  former  drug,  if  needed,  in  24  h.  We
aited  a  minimum  of  2  h  (ideally  6),  after  initiating  standard
ormonal  therapy.  We  attempted  to  reduce  the  dose  of  the
asopressors,  mainly  of  the  noradrenalin,  if  it  was  being
dministered,  and  the  procurement  of  the  heart  was  made
deally  within  6  h  after  the  hormonal  therapy.  Open  heart
ertiary  survey  was  made  by  the  surgeon  and  this  was  the
ain  guideline  for  obtaining  procurement.
The  variables  measured  were  as  follows:  total  ischaemic
ime,  cardiopulmonary  derivation  time,  recipient  aortic
lamping  time,  postoperative  complications  and  primarily
he  survival  of  the  procured  organ  in  the  immediate  (ﬁrst
4  h),  intermediate  (1st--7th  day)  and  delayed  (8th--30th
ay)  postoperative  period.
Statistical  method:  A  descriptive  statistical  method  was
sed  to  characterise  the  sample  of  this  patient  series.
esults
0  patients  received  transplants,  11  women  (36.66%)  and
9  men  (63.33%)  aged  44.3  ±  12.92  (19--63  years  of  age),
ith  the  following  diagnoses  as  the  causes  of  end-stage  car-
iac  failure:  idiopathic  enlargement  in  15  patients  (50%),
schaemic  cardiopathy  in  13  (43.3%),  restrictive  in  one
atient  (3.3%),  Ebstein’s  disease  in  one  case  (3.3%).  The
unctional  class  of  the  New  York  Heart  Association  (NYHA)
as:  III  in  eight  patients  (26.6%)  and  IV  in  22  patients
73.3%).
All  heart  transplants  performed  were  orthotopic,  using
he  biatrial  technique  in  12  patients  (40%)  and  bicaval  tech-
ique  in  18  patients  (60%).  Cardiopulmonary  derivation  time
as  125.3  ±  26.34  min  (range  69--196  min),  total  ischaemia
ime  was  225.03  ±  61.13  min  (119--366  min),  aortic  clam-
ing  of  the  ‘‘hot  ischemia’’receptor  was  78.56  ±  12.62  min
55--109  min).  The  average  difference  in  total  ischaemia
ime  and  aortic  clamping  of  the  average  receptor  was
46.47  min.
Donor  data  were  as  follows:  7  women  (23.3%),  23  men
76.6%),  aged  22.5  ±  7.3  (range  between  15  and  45  years  of
ge).
Immediate  mortality  was  3.3%  (one  patient),  intermedi-
te  3.3%  (one  patient)  and  delayed  3.3%  (one  patient),  with
 total  30-day  mortality  of  10%  (3  patients)  and  survival  rate
f  90%  (27  patients).
The  left  ventricle  ejection  fraction  prior  to  the  heart  pro-
urement  was  on  average  55%,  obtained  by  echocardiogram
n  only  18  patients  (90%).  The  left  ventricle  ejection  frac-
ion  in  the  immediate  postoperative  period  was  an  average
f  45%,  intermediate  of  60%  and  delayed  of  68%.
Complications  presented  were:  acute  kidney  failure  in
0%  (12  patients)  of  whom  2  patients  (6.6%)  required  kidney
eplacement  therapy  with  continual  veno-venous  haemodi-
ﬁltration  (Prisma®).  Right  cardiac  failure  of  the  organ
resented  in  6  patients  (20%);  sinusal  node  dysfunction,  in
 patients  (20%);  delirium  in  5  patients  (16.6%);  postopera-
ive  haemorrhaging  in  2  patients  (6.6%),  and  liver  failure
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n  2  patients  (6.6%).  One  patient  presented  with  pneumo-
ia  (3.3%),  another  with  cerebral  haemorrhaging  (3.3%)  and
nother  with  massive  pulmonary  thromboembolia  (3.3%).
The  cause  of  death  in  the  immediate  postoperative
eriod  of  the  one  patient  (3.3%)  was  primary  graft  dysfunc-
ion,  in  the  intermediate  period  it  was  massive  pulmonary
mbolism  (3.3%)  and  in  the  case  of  delayed  (3.3%)  it  was
neumonia  and  septic  shock  with  positive  culture  testing  of
cinetobacter  baumannii. The  mortality  rate  during  the  ﬁrst
0  days  was  10%  (3  patients).
iscussion
eart  transplant  is  an  undisputedly  good  option  for  end-
tage  heart  failure  and  the  success  of  a  transplant  is  due  to
any  factors.  One  of  these  is  the  ventricular  function  of  the
onated  organ.11,12 During  brain  death  a  series  of  hormonal
hanges  occur:  antidiuretic  or  vasopressin  levels  drop,  thy-
oid  hormones  are  too  low,  blood  interleukins  increase,
here  is  a  change  in  the  aerobic  cycle  in  cells.4 In  addition  to
his,  during  brain  death  ‘‘adrenergic  storm’’  occurs  whereby
erum  levels  of  noradrenaline  are  raised  substantially,  with
evastating  consequences  on  the  potentially  donated  heart
ncluding:  damage  of  the  myocyte,  increased  in  systolic
nd  diastolic  biventricular  cardiac  failure  (predominantly
ight  ventricle),  arrhythmias,  petechial  haemorrhaging  in
he  subendocardium,  poorer  endothelial  functioning  and
oss  of  vasomotor  tone,  which  induces  a  depression  of  poten-
ially  reversible  myocardial  contractibility.7,13
All  hormonal  events  led  to  the  creation  of  the  Crys-
al  Consensus  scheme  for  the  use  of  hormones  for
escue  of  potential  marginal  donated  hearts,  with  excel-
ent  outcome.9 This  scheme  uses  methylprednisolone  at
5  mg/kg,  triiodothyrone  4  g  U  IV,  vasopressin  1U  IV  and
nsulin  1U/h  IV.14,15
With  the  application  of  the  hormonal  Crystal  Consensus
escue  scheme,  many  authors  have  reported  better  recovery
f  hearts  with  ejection  fraction  of  marginal  left  ventricle,
ungs  and  kidneys  and  that  a  lower  dose  of  vasopressors  is
equired  prior  to  procurement  of  thoracic  organs.10
In  this  paper  we  modiﬁed  the  form  of  administration  and
he  Crystal  Consensus  protocol.  We  used  2  hormonal  drugs,
ethylprednisolone  at  15  mg/kg  IV  bolus  and  levothyrox-
ne  200  g  by  the  enteral  route,  instead  of  3  or  4  hormonal
rugs,  like  those  of  the  protocol  mentioned.  Hormonal  ther-
py  was  administered  routinely,  separately  from  the  left
entricle  fraction  ejection  found  by  echocardiogram  dur-
ng  the  ﬁrst  assessment  and  not  as  a rescue  of  marginal
rgan  grafts  with  left  ventricle  ejection  fraction  under  40%.
e  waited  at  least  2  h  (like  in  the  Crystal  Consensus  proto-
ol)  after  administration  of  the  dual  hormonal  scheme  for
he  expected  effects  and  a maximum  of  24  h.  Final  deter-
ination  for  obtaining  the  organ  grafts  for  transplantation
as  decided  by  an  objective  assessment  of  the  open  heart
ardiovascular  surgeon.
Rosendale  et  al.15 in  their  work  used  3  rescue  hor-
ones  (steroids,thyroids  and  vasopressin),  in  addition  to
ariable  combinations  of  2  of  them  and  also  individually.
n  this  study  we  demonstrated  that  only  the  combination  of
he  triple  hormonal  scheme  (steroids,  thyroid  hormone  and
asopressin)  was  greater  than  the  combination  of  steroids
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and  thyroid  hormones,  both  in  the  presentation  of  primary
graft  dysfunction  (odds  ratio  of  0.45  vs.  0.66),  mortality  at
one  month  (odds  ratio  of  0.47  vs.  0.67),  and  at  12  months
90%  vs.  83.3%.  The  other  dual  or  individual  combinations  had
lower  results,  the  combination  of  steroids  and  vasopressin
IV  being  the  poorest.
In  our  work  we  used  steroids  (methylprednisolone)  and
a  thyroid  hormone  (levothyroxine)  in  a  routine  manner  and
our  results  were  a  mortality  of  3.3%  in  the  immediate  post-
operative  period,  3.3%  intermediate  and  3.3%  delayed,  with
a  10%  total  during  the  ﬁrst  postoperative  month.
Left  ventricle  ejection  fraction  in  our  study  was  initially
45%  and  rose  to  60%  during  the  intermediate  period,  and
improved  in  the  delayed  period  to  65%.  This  was  in  accor-
dance  with  the  studies  made  by  Berman  et  al.7 in  which
the  recovery  of  the  heart  was  presented  between  day  7
and  14,  where  it  mimicked  cardiac  dysfunction  suffered
during  brain  death,  subarachnoid  haemorrhaging  and  Takot-
subo  syndrome  for  its  similarity  in  adrenergic  discharge,
histopathological  lesions,  recuperation  and  non  coronary
lesions.
Thirty  days  mortality  rate  was  10%,  but  mortality
attributed  to  primary  dysfunction  of  the  graft  procured  was
3.3%.  This  is  important  because  graft  dysfunction  did  not  sig-
niﬁcantly  present  in  the  patients  who  received  the  standard
dual  hormonal  therapy,  providing  an  opportunity  for  better
patient  recovery  with  correct  management.
Of  the  presented  complications  it  is  important  to  men-
tion  multifactorial  acute  kidney  failure  at  a  high  percentage
(40%).  This  high  percentage  is  similar  to  that  reported  in
medical  literature.16,17 Right  cardiac  failure  presented  in
20%  of  patients  but  recuperation  took  place  between  4
and  7  days,  in  accordance  with  that  previously  mentioned
regarding  left  ventricle  ejection  fraction  recovery.7
Total  ischaemia  time  was  225.03  min  (within  the  time
ranges  recommended  by  international  guides,  which  is  under
240  min18).  The  difference  between  total  ischaemia  and  cold
ischaemia  time,  or  aortic  clamping  time  of  the  receptor  was
146.47  min,  attributed  to  the  transportation  time  from  the
place  of  organ  origin.  The  latter  was  mostly  a  different  ori-
gin  from  our  centre.  This  was  the  reason  why  total  ischaemia
time  was  prolonged,  as  reported  in  the  previous  study  by
Careaga-Reyna  et  al.19
Our  study  consists  of  a  small  number  of  patients  and  if
we  take  into  consideration  that  a  hospital  which  carries  out
10--25  heart  transplants  yearly  is  considered  to  be  of  inter-
mediate  production  on  a  worldwide  level,20 we  believe  it  is
an  appropriate  number  and  requires  follow-up  to  assess  the
outcome  at  6  months,  and  1  and  5  years.
Conclusion
Hormonal  rescue  was  created  for  the  management  of
donated  hearts  with  left  ventricle  ejection  fraction  (≤  40%).
Based  on  the  Crystal  Consensus  Scheme,  we  used  hormonal
rescue  therapy  in  all  heart  donations,  although  their  left
ventricle  ejection  fraction  was  ≥  50%.  Using  a  dual  hor-
monal  rescue  scheme  with  steroids  (methylprednisolone
15  mg/kg/bolus  IV)  and  thyroid  hormones  (levothyroxine
200  g  by  the  enteral  route),  our  group  reached  the  follow-
ing  conclusions:
1233
.  The  possibilities  of  primary  graft  dysfunction  and  its  asso-
ciation  with  mortality  was  lowered  to  3.3%.
.  Mortality  during  the  ﬁrst  30  days  fell  to  10%  in  total.
.  Study  control  and  follow-up  over  a  longer  period  of  6,
and  12  months  is  required.
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